Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence - 02/10/14
Abstract |
Background |
Filaggrin is an epidermal protein that has a role in skin barrier function. Filaggrin loss-of-function (FLG-LOF) mutations are a significant risk factor for eczema and atopy, but their association with food allergy (FA) is less clear.
Objective |
We explored the longitudinal relationship between 3 common FLG-LOF mutations and FA using the Isle of Wight birth cohort.
Methods |
FA diagnosis was based on recognized allergic reactions within 4 hours after exposure to known food allergens. Food allergen sensitization (FAS) was identified by using skin prick tests conducted between 1 and 18 years of age to a range of food allergens. Three FLG mutations were genotyped in 1150 (79%) of 1456 children. The temporal relationships between FA, FAS, and eczema in children with FLG mutations were explored by using path analysis with total, direct, and indirect effect models.
Results |
There was a significant total effect of FLG-LOF mutations on the risk of FA in later childhood at the ages of 10 (odds ratio, 31.46; 95% CI, 2.86 to >100) and 18 (odds ratio, 4.25; 95% CI, 1.55-11.61) years. Path analysis showed that there was no direct effect of FLG-LOF mutations on FA at any age; however, an indirect effect was found on FA at all ages through eczema and FAS in the earlier years.
Conclusion |
FLG-LOF mutations are associated with FA in older children through eczema and FAS during early childhood. Our results highlight a biologically plausible pathway, which suggests that skin barrier function is important in the development and persistence of FA.
Le texte complet de cet article est disponible en PDF.Key words : Food allergy, filaggrin, FLG-LOF, food allergen sensitization, path analysis, prediction, eczema
Abbreviations used : FA, FAS, FLG, FLG-LOF, IOW, OR, SPT
Plan
Supported by National Institutes of Health project grants R01-HL082925, R01-AI061471, and R01-AI091905. The 10-year follow-up of this study was funded by the National Asthma Campaign, UK (grant no. 364). |
|
Disclosure of potential conflict of interest: This study was funded by the National Institutes of Health. The authors declare that they have no other relevant conflicts of interest. |
Vol 134 - N° 4
P. 876 - octobre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?